In response to the COVID-19 situation, OCLI is following enhanced safety protocols consistent with guidelines put forth by the CDC and the World Health Organization (WHO) to protect our patients and colleagues. Click here to learn about how we are keeping you safe.

Alcon Receives FDA Approval for ReSTOR +3.0

December 26, 2008

 

Alcon, Inc. announced the approval of their ReSTOR +3.0 intraocular lens for the treatment of presbyopia following cataract surgery and refractive lens exchange.  This IOL will complement their already approved ReSTOR +4.0.

So what does this mean to our refractive cataract patients?  The ReSTOR +4.0 is an excellent multifocal IOL that allows my patients both near and far vision without glasses.  Some patients receiving this lens will complain that they cannot see intermediate distances well.  These patients need to sit close to computer monitors to see clearly.
The ReSTOR +3.0 will provide better intermediate vision.  Most likely patients will begin to receive a +3.0 in one eye and a +4.0 in the other eye.  This will afford these patients excellent near, intermediate, and distance vision without glasses!

For our patients that wish to rid themselves of bifocals, the results from premium IOLs have been excellent.  The introduction of the +3.0 will only enhance these outcomes.  OCLI will be one of the first practices in the country to have access to the ReSTOR 3.0 within the first few weeks of 2009.

Back to our blog

Services offered at OCLI

Our world-class team of professionals at OCLI can help you with the latest treatment options for you.

Request an appointment

* required